Cargando…
A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
Objectives: This study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD). Background: Developme...
Autores principales: | Allen, Hugh D., Flanigan, Kevin M, Thrush, Philip T., Dvorchik, Igor, Yin, Han, Canter, Charles, Connolly, Anne M., Parrish, Mark, McDonald, Craig M., Braunlin, Elizabeth, Colan, Steven D., Day, John, Darras, Basil, Mendell, Jerry R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871420/ https://www.ncbi.nlm.nih.gov/pubmed/24459612 http://dx.doi.org/10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865 |
Ejemplares similares
-
Correction: A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
Publicado: (2015) -
A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2017) -
Medical management of muscle weakness in Duchenne muscular dystrophy
por: Rivera, Sarah R., et al.
Publicado: (2020) -
Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Janssen, Paul M. L., et al.
Publicado: (2014) -
The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2015)